Patents by Inventor Frederick West

Frederick West has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF
    Publication number: 20220306603
    Abstract: The current application relates to pyronaridine or 6-chloro-2-methoxyacridine analogs having binding affinity for the ERCC1-XPF hetero-dimerization interface. The compounds can be used for targeting DNA repair in tumor cells via ER-CC1-XPF inhibition, therefore improving the therapeutic benefit of irradiation or other cancer treatment, or reducing the dosage and adverse effects associated with such treatment.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 29, 2022
    Inventors: Frederick WEST, Jack TUSZYNSKI, Michael WEINFELD, Khaled Hassan BARAKAT, Ahmed H. ELMENOUFY, Francesco GENTILE, Feridoun KARIMI-BUSHERI, Claudia WEILBEER
  • Fluorinated fructose derivatives for PET imaging
    Patent number: 8501154
    Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: August 6, 2013
    Assignee: The Governors of the University of Alberta
    Inventors: Chris Cheeseman, Frederick West, Tina Grant, Brendan Trayner, John Mercer, Andrei Manolescu
  • FLUORINATED FRUCTOSE DERIVATIVES FOR PET IMAGING
    Publication number: 20130078184
    Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 28, 2013
    Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Chris CHEESEMAN, Frederick WEST, Tina GRANT, Brendan TRAYNER, John MERCER, Andrei MANOLESCU
  • Fluorinated fructose derivatives for PET imaging
    Patent number: 8293208
    Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: October 23, 2012
    Assignee: The Governors of the University of Alberta
    Inventors: Chris Cheeseman, Frederick West, Tina Grant, Brendan Trayner, John Mercer, Andrei Manolescu
  • FLUORINATED FRUCTOSE DERIVATIVES FOR PET IMAGING
    Publication number: 20100290988
    Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.
    Type: Application
    Filed: May 15, 2009
    Publication date: November 18, 2010
    Inventors: Chris CHEESEMAN, Frederick WEST, Tina GRANT, Brendan TRAYNER, John MERCER, Andrei MANOLESCU
  • Cobalamin conjugates for anti-tumor therapy
    Publication number: 20050054607
    Abstract: The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5?-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells.
    Type: Application
    Filed: September 10, 2003
    Publication date: March 10, 2005
    Inventors: Ned Weinshenker, Frederick West, Barbara Araneo, Weiping Li